Table 2.
Clinical measurements of transgender patients.
| Laboratory test | Reference range | Patient #1 | Patient #2 | Patient #3 |
|---|---|---|---|---|
| Prothrombin time | 10-13.2 seconds | 10.8 | ||
| Activated partial thromboplastin time | 26-38 seconds | 31 | 26 | |
| D-dimer | 0-500 ng/mL fibrinogen equivalent units | 385 | 394 | 33791→496→428 |
| Fibrinogen | 200-450 mg/dL | 244 | 356 | 649→541 |
| Fibrinogen antigen | 180-350 mg/dL | 409 | ||
| PAI-1 activity | 0-27 International Units/mL | 22 | 26 | <4 |
| PAI-1 antigen | 4.0-43.0 ng/mL | 37 | ||
| Alpha2-antiplasmin | 80-150% | 133 | 124 | 117 |
| Antithrombin activity | 75-135% | 110 | ||
| Antithrombin antigen | 72-124% | 88 | ||
| Factor II G20210A mutation | Normal | Normal | ||
| Factor V Leiden mutation | Normal | Normal | ||
| Protein S, Free (LC) | 57-157% | 101 | ||
| Protein S, total (LC) | 60-150% | 120 | ||
| Protein S, functional (LC) | 63-140% | 108 | ||
| Protein C | 70-140 % activity | 67→51 | ||
| Anti-β2 glycoprotein 1 Ab IgM | 0-32 β2 GP1 IgM units | <9→<9 | <9 | |
| Anti-β2 glycoprotein 1 Ab IgG | 0-20 β2 GP1 IgG units | <9→<9 | <9 | |
| Anti-β2 glycoprotein 1 Ab IgA | 0-25 β2 GP1 IgA units | <9→<9 | <9 | |
| Anti-cardiolipin Ab IgM | 0-10 phospholipid units | 18→16 | <10 | |
| Anti-cardiolipin Ab IgG | 0-10 phospholipid units | <10→<10 | <10 | |
| Anti-cardiolipin IgA | 0-10 phospholipid units | <10→<10 | <10 | |
| partial thromboplastin time (Lupus anticoagulant) | 0-51.9 seconds | 30.6 | ||
| dRVVT (LC) | 0-47.0 seconds | 45.1 | ||
| Lupus anticoagulant Interpretation (LC) | Not detected | Not detected | ||
| Homocysteine | 3.2-10.7 μmol/L | 7.3 | 10 | |
| Lipoprotein A | <=75.0 nmol/L | 16.3 | 32.4 | |
| Erythrocyte sedimentation rate | 0-30 mm/hr | 24→20 | <1 | |
| C-reactive protein | 0-9.99 mg/L | 8.61→8.57 | 2.82 | |
| Total cholesterol | 135-200 mg/dL | 222 | 148 | 150 |
| Low density lipoprotein | 0-110 mg/dL | 144 | 67 | 54 |
| High density lipoprotein | 35/80 mg/dL | 35 | 34 | 37 |
| Triglycerides | 0-150 mg/dL | 244 | 430 | 73 |
| Hemoglobin A1c | 3.6-5.7% | 5.6 | 8.6 | 5.9 |
Arrows represent repeated measurements. Patient 2 underwent repeat diagnostics 3 months apart. For patient 3, D-dimer was measured at the time of pulmonary embolism, then 1 and 11 months later; fibrinogen levels were measured 24 hours apart in the week following the pulmonary embolism; Protein C was first measured a month after the pulmonary embolism, and then 10 months later.
Ab, antibody; dRVVT, dilute Russell viper venom test; LC, liquid chromatography; PAI-1, plasminogen activator inhibitor-1.